DARSTIN®
Specific treatment of benign breast conditions. Mastodynia. Breast tenderness, in isolation or associated with: Contraceptive treatment. Premenstrual syndrome. Early pregnancy. Benign mastopathies.
1 - NAME OF THE MEDICINAL PRODUCT
Darstin® 10 mg/g gel
2 - QUALITATIVE AND QUANTITATIVE COMPOSITION
Each gram of gel contains: 10 mg of progesterone.
For the full list of excipients, see section 6.1.
3 - PHARMACEUTICAL FORM
Translucent gel.
4 - CLINICAL PARTICULARS
4.1 Therapeutic indications
Specific treatment of benign breast conditions.
Mastodynia
Breast tenderness, in isolation or associated with:
Benign mastopathies
4.2 Posology and method of administration
Posology
Apply 5 g of gel (one spatula measure for each breast) to the skin of the breasts every day, even during menstruation.
The duration of treatment depends on the indication and will be decided by the doctor on an individual basis.
Method of administration
Topical use
Hold the end of the spatula with one hand and the tube with the other and squeeze the gel along the length of the spatula. This quantity is the right dose for one breast (2.5 g). Repeat for the other breast.
4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
4.4 Special warnings and precautions for use
Since it is a water-alcohol solution, it should not be applied directly to mucous membranes.
Frequent applications may cause skin irritation and dryness.
4.5 Interaction with other medicinal products and other forms of interaction
No significant clinical interaction has been observed in the studies conducted.
4.6 Fertility, pregnancy and lactation
The data obtained do not suggest that Darstin® has an influence on pregnancy.
Since Darstin® does not have any systemic effects, it can be used during breast-feeding.
4.7 Effects on ability to drive and use machines
Darstin® has no influence on the ability to drive and use machines.
4.8 Undesirable effects
Darstin® does not generally cause adverse effects. However, those described below may occur:
Skin and subcutaneous tissue disorders
Frequency not known (cannot be estimated from the available data): skin irritation and dryness.
4.9 Overdose
Due to the particular pharmacokinetics of this product, there is no risk of overdose.
5 - PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties:
Pharmacotherapeutic group: progestogens, pregnen (4) derivatives.
ATC code: G03DA04.
Mechanism of action
Darstin® is a pure progesterone dispersed in a suitable excipient for percutaneous administration. Thanks to its anti-oestrogenic action, it locally corrects the imbalance between oestrogens and progesterone.
It acts directly on the mammary gland, where the hormone is concentrated. In general, Darstin® has no adverse effects, so it is well tolerated.
Darstin® prevents the vascular and cellular effects of a local progesterone deficiency in the mammary glands. At this level, progesterone:
5.2 Pharmacokinetic properties
Absorption
The absorption coefficient is about 10% of the administered dose.
Biotransformation
Eighty percent of the absorbed drug is metabolised in the mammary gland, while only 20% reaches the systemic circulation.
Elimination
The maximum elimination of the metabolites takes place after 48 hours.
5.3 Preclinical safety data
Safety and local tolerance tests:
In the studies conducted, the skin surface where the product was applied was observed regularly and also at the end of treatment. The skin surface where the product is applied remains intact after finishing treatment.
6 - PHARMACEUTICAL PARTICULARS
6.1 List of excipients
6.2 Incompatibilities
None described.
6.3 Shelf life
3 years.
6.4 Special precautions for storage
Store below 25°C and keep the container tightly closed after each application.
6.5 Nature and contents of container
Lacquered aluminium tube with gold-coloured inner varnish and sealed opening containing 80 g with applicator spatula.
6.6. Special precautions for disposal and other handling
No special requirements.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
7 - MARKETING AUTHORIZATION HOLDER
SEID, S.A.
Carretera de Sabadell a Granollers, Km. 15 08185 – Lliçà de Vall (Barcelona)
8 - MARKETING AUTHORIZATION NUMBER(S)
55.868
9 - DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
14 April 1983
10 - DATE OF REVISION OF THE TEXT
October 2003
Summary of product characteristics Darstin®
Carretera de Sabadell a Granollers Km 15 08185 Lliçà de Vall (Barcelona, Spain)
+34 93 844 57 30
Multilingual WordPress with WPML